Randomized, double-blind, placebo-controlled phase III study (ASAP III study) to assess the efficacy and safety of Abatacept treatment in patients with primary Sjögren*s syndrome (ASAP III study = Abatacept Sjögren Active Patients phase III study) - ASAPIII

niversitair Medisch Centrum Groningen0 个研究点目标入组 80 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

阶段: 3 期
状态: 已完成
发起方: niversitair Medisch Centrum Groningen
入组人数: 80

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 99（—）

入选标准

•- Signed written informed consent
•- ESSDAI * 5
•- Female or male * 18 years
•- pSS according to the American European Consensus Group (AECG) classification criteria (6)
•- Disease duration * 7 years at the moment of inclusion
•- pSS proven by parotid gland biopsy with characteristic features of SS
•- Women of child bearing (WOCBP) potential must be using an acceptable method of contraception (i.e. oral, injected or implanted hormonal contraceptives, barrier contraception, intra-uterine devices, or sterilization) to avoid pregnancy throughout the study and for up to 10 weeks after the last dose of study drug in such a manner that the risk of pregnancy is minimized.
•- Sexually active fertile men must use effective birth control if their partners are WOCBP

排除标准

•- Presence of any other connective tissue disease.
•- Flow rate of stimulated whole saliva * 0.05 ml/min in patients without extraglandular manifestations.
•- Positive pregnancy test or breast-feeding women.
•- Women with a child-bearing potential who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for the entire study period.
•- History of alcohol or drug abuse or current alcohol or drug abuse.
•- History of any malignancy in the past 5 years, including MALT lymphoma in the last 5 years, or with a current suspicion for cancer, other than non-melanoma skin cell cancers (NMSC), cured by local resection or carcinoma in situ. Existing NMSCs should be removed, the lesion site healed, and residual cancer ruled out before administration of the study drug.
•- Subjects with evidence (as assessed by the investigator) of active or latent bacterial or viral infections at the time of potential enrollment, including subjects with evidence of human immunodeficiency virus (HIV) detected during screening.
•- History of chronic or recurrent serious infections. (e.g. chronic pyelonephritis, osteomyelitis or bronchiectasis).
•- Subjects with serious bacterial infections within the last 3 month, unless treated and resolved with antibiotics
•- Subjects with herpes zoster or cytomegalovirus that resolved less than 2 months before potential enrollment.
•- Subjects at risk for TB. Specifically excluded from this study will be subjects with a history of active TB within the last 3 years, even if it was treated; a history of active TB greater than 3 years ago, unless there is documentation that the prior anti-TB treatment was appropriate in duration and type; current clinical, radiographic, or laboratory evidence of active TB; and latent TB that was not successfully treated (* 4 weeks).
•- Subjects must not be positive for hepatitis B surface antigen.
•- Subjects who are positive for hepatitis C antibody if the presence of hepatitis C virus was also shown with polymerase chain reaction or recombinant immunoblot assay.
•- Subjects who have received any live vaccines within 3 months before potential enrollment.
•- Underlying cardiac, pulmonary, metabolic, renal, hepatic, gastrointestinal, haematological or neurological conditions, chronic or latent infectious diseases or immune deficiency which places the patient at an unacceptable risk for participation in the study.
•- Use of prednisone *10 mg less than 1 month before inclusion.
•- Use of pilocarpine, hydroxychloroquine, methotrexate, cyclophosphamide, cyclosporin, azathioprine, mycophenolate mofetil (MMF) and leflunomide less than 1 month before inclusion.
•- Use of biologicals:
•oUse of abatacept less than 6 months or rituximab less than 12 months before inclusion
•oPrevious use of abatacept or rituximab if treatment with abatacept or rituximab was discontinued because of safety reasons or failure of treatment
•oPrevious use of other biological DMARDS than abatacept or rituximab, either marketed or under investigation
•- Lab abnormalities:
•a. Serum creatinine *2.8 mg/dl (250 µmol/l)
•b. ASAT or ALAT outside 1.5 x upper normal range of the laboratory
•c. Hb *9 g/dl (5.6 mmol/l) for males and 8.5 g/dl (5.3 mmol/l) for females
•d. Neutrophil granulocytes less than 0.5 x 109/l
•e. Platelet count less than 50 x 109/l
•- Any other laboratory test results that, in the opinion of the investigato

研究者

发起方

niversitair Medisch Centrum Groningen

相似试验

进行中（未招募）

不适用

Abatacept treatment in primary Sjögrens SyndromePrimary Sjögren's syndrome (pSS)MedDRA version: 16.1Level: LLTClassification code 10042846Term: Syndrome Sjogren'sSystem Organ Class: 100000004859

EUCTR2014-000417-31-NLniversity Medical Center Groningen

进行中（未招募）

1 期

Randomized, double-blind, placebo-controlled phase II pilot study of the impact of mesalazine enemas on the mucosal gut flora in patients with inflammatory bowel disease - Impact of mesalazine vs placebo on mucosal gut flora in IBD patientsActive inflammatory bowel disease, i.e. either left-sided ulcerative colitis or Crohn´s Disease (Colon) with signs of inflammation within 40 cm ab ano.MedDRA version: 8.1Level: LLTClassification code 10021972Term: Inflammatory bowel disease

EUCTR2006-004162-13-DECharité Universitätsmedizin, Campus Charité Mitte40

已完成

1 期

Phase Ib-IIb trial of the live oral cholera vaccine 638 in adult volunteers in Mozambique.Cholera diseaseCholera/ prevention & controlHealthy VolunteersVibrio InfectionsGram-Negative Bacterial InfectionsBacterial InfectionsWaterborne DiseasesEnvironmental Illness

RPCEC00000051Finlay Institute120

进行中（未招募）

不适用

Randomized, double-blind, placebo controlled phase II study comparing the safety of MDX-010 BMS-734016 administered with or without prophylactic oral budesonide Entocort EC in patients with unresectable stage III or IV malignant melanoma. - NDMedDRA version: 6.1Level: HLTClassification code 10027156Melanoma

EUCTR2005-002678-31-ITBRISTOL-M.SQUIBB100

进行中（未招募）

不适用

EUCTR2009-014725-16-DEAIO Studien gGmbH